Xeris Biopharma Holdings, Inc. has recently filed a Form 144, indicating that officer Beth Hecht plans to sell 75,000 shares of the company. This transaction is significant as it reflects ongoing executive activity and stock management within the company.

Background

Xeris Biopharma Holdings, Inc. operates in the pharmaceutical preparations sector, classified under SIC code 2834. The company trades on the Nasdaq under the ticker symbol XERS. As a large accelerated filer, Xeris is subject to stringent reporting requirements and is focused on advancing its biopharmaceutical products.

What the Filing Says

The filing, dated November 2, 2026, states that the shares to be sold were acquired through restricted stock units that vested between January 3, 2025, and January 31, 2025. The approximate sale date for the shares is also noted as November 2, 2026, with an aggregate market value of $803,250.

Impact

This sale may impact shareholders and potential investors by signaling the liquidity strategies of the company's executives. It also raises questions about insider trading practices and market confidence in Xeris Biopharma's future.

What's Next

The filing does not say what happens next.

Details of Previous Sales

In addition to the upcoming sale of 75,000 shares, Beth Hecht has engaged in several transactions over the past three months under a 10b5-1 plan. Specifically, Hecht sold 16,666 shares on August 3, 2026, for gross proceeds of approximately $133,553.66, followed by another sale of the same number of shares on September 1, 2026, which generated about $141,433.67. Most recently, on October 1, 2026, she sold another 16,666 shares, resulting in gross proceeds of around $156,791.73. These transactions indicate a consistent pattern of selling shares, which may reflect a strategic approach to liquidity management.

Brokerage Information

The shares being sold by Hecht will be facilitated through Morgan Stanley Smith Barney LLC Executive Financial Services, a well-known brokerage firm located at 1 New York Plaza, 8th Floor, New York, NY. This partnership may provide Hecht with the necessary resources and market expertise to execute her sales effectively.

Outstanding Shares

As of the filing date, Xeris Biopharma has a total of 182,320,306 shares outstanding. This figure is crucial for understanding the potential impact of insider sales on overall share value and market perception.

Future Reporting

The filing does not provide information on any future plans for additional stock sales by Hecht or other executives, nor does it indicate any changes in the company's overall stock management strategy.